Development
Ocular Therapeutix, Inc.
OCUL
$8.23
-$0.10-1.20%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -29.22M | -516.00K | -20.68M | -30.32M | -15.54M |
| Total Depreciation and Amortization | 958.00K | 890.00K | 652.00K | 483.00K | 491.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.36M | -14.33M | 4.54M | 12.36M | 228.00K |
| Change in Net Operating Assets | -6.55M | 6.22M | -4.58M | -2.50M | -2.14M |
| Cash from Operations | -22.45M | -7.73M | -20.08M | -19.97M | -16.96M |
| Capital Expenditure | -459.00K | -259.00K | -1.99M | -3.38M | -2.15M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -459.00K | -259.00K | -1.99M | -3.38M | -2.15M |
| Total Debt Issued | 0.00 | 82.47M | 0.00 | 2.00M | -- |
| Total Debt Repaid | 0.00 | -26.13M | 0.00 | -2.00M | -- |
| Issuance of Common Stock | 108.17M | 770.00K | 9.65M | 78.00K | 458.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -5.18M | -- | -- | -- |
| Cash from Financing | 108.17M | 51.94M | 9.65M | 78.00K | 458.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 85.26M | 43.94M | -12.42M | -23.27M | -18.65M |